Fresenius Medical Care Completes Acquisition of NxStage Medical
Thousands of end stage renal disease experts turn to Renal Therapies Group for pharmaceuticals and the most prescribed technologies in the industry.
Power your practice with our resources. We're here to help support your patients and your thriving practice.
Every day, we’re working tirelessly to transform the future of healthcare. Because every patient deserves treatment as strong as they are.
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
New Leadership and Team to Further Company’s Commitment to Home Therapies
WALTHAM, Mass. – May 6, 2019 – Fresenius Medical Care North America (FMCNA), the nation’s leading provider of kidney care products and services, has announced organizational changes following its merger with NxStage Medical, Inc. As part of these changes, Jeff Burbank and Joe Turkhave joined the FMCNA senior leadership team in new roles that will help lead the company’s innovation and expansion of home therapies.
Burbank, former NxStage Founder and Chief Executive Officer, will serve as the company’s first Chief Technology Officer (CTO), reporting to Bill Valle, CEO of FMCNA. Turk, who previously served as President at NxStage, will also report to Valle as President of Home and Critical Care Therapies, leading a newly formed team within FMCNA.
“I’m thrilled that we are bringing these talented groups together under Jeff and Joe’s leadership to ensure we continue to seamlessly integrate the incredible experience and groundbreaking technology from the NxStage team directly into Fresenius Medical Care North America,” said Valle. “Under their leadership, we will centralize our focus on home therapies that are giving life back to our patients with kidney failure by offering more freedom, control and better health.”
Burbank’s vision that patients with kidney failure should be able to easily conduct their hemodialysis at home created an extraordinary track record of innovation and groundbreaking technology at NxStage. As CTO, Burbank will help grow FMCNA’s innovative product offerings and connected health platforms.
Turk brings 18 years of experience with NxStage, most recently managing the company’s worldwide product business. In his new role at FMCNA, he will be responsible for expanding access to home dialysis through the most innovative products on the market, ensuring all patients can choose the treatment modality that is right for their individual needs.
In March 2019, U.S. Health and Human Services Secretary Alex Azar committed government support to help boost home dialysis in a speech before the National Kidney Foundation, saying it’s “better for patients’ independence and self-sufficiency, and better for their physical health.” FMCNA is also committed to significantly increasing the number of patients using home dialysis.
About Fresenius Medical Care North America
Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities, outpatient cardiac and vascular labs and urgent care centers, Fresenius Medical Care North America provides coordinated healthcare services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world’s largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products and renal pharmaceuticals. For more information, visit the FMCNA website at https://fmcna.com.